- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 933 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Fresno, California • La Mesa, California • Lancaster, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 145,369
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3, Endometrial Cancer, Endometrial Cancer Stage
- Interventions
- Exercise, Attention Control
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Overactive Bladder
- Interventions
- Solifenacin, Placebo
- Drug · Other
- Lead sponsor
- Cleveland Clinic Florida
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Weston, Florida
- Conditions
- Graft Versus Host Disease
- Interventions
- [18F]F-Ara-G
- Drug
- Lead sponsor
- CellSight Technologies, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Multiple Sclerosis
- Interventions
- ketamine
- Drug
- Lead sponsor
- Alta Bates Summit Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Berkeley, California
- Conditions
- Acute Kidney Injury, Surgery Complications, Anesthesia
- Interventions
- EHR-Embedded AKI Risk Score, EHR-Embedded AKI Risk Score with Best Practice Advisory
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,518 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Eye Diseases
- Interventions
- Next Generation Ophthalmic Irrigating Solution (NGOIS), BSS Plus
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dental Caries
- Interventions
- xylitol wipe, placebo wipe
- Dietary Supplement
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
- Interventions
- irinotecan hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fanconi Anemia
- Interventions
- Cyclophosphamide, Fludarabine, Total body irradiation (TBI)
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
- Interventions
- Not listed
- Lead sponsor
- Target PharmaSolutions, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Colorado Springs, Colorado • Clearwater, Florida • Louisville, Kentucky + 2 more
- Conditions
- Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Triple-Negative Breast Carcinoma, Progesterone Receptor Negative, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Corona, California • Duarte, California • Lancaster, California + 4 more
- Conditions
- Alcohol-Related Disorders, Opioid-Related Disorders, Substance-Related Disorders
- Interventions
- 30% Nitrous oxide, Placebo, 0.2% sevoflurane, 0.4% sevoflurane, 0.6% sevoflurane
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Not listed
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1998
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Mild Cognitive Impairment
- Interventions
- Voice-activated smart speakers
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Metastatic Melanoma, Metastatic Kidney Cancer
- Interventions
- Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide, Fludarabine
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
- Interventions
- Brachyury-TRICOM, Entinostat, M7824, Ado-trastuzumab emtansine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type 2 Diabetes
- Interventions
- Muraglitazar
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Mesa, Arizona + 67 more
- Conditions
- Kidney Transplant Rejection
- Interventions
- AT-1501, Tacrolimus
- Drug
- Lead sponsor
- Eledon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 23 more
- Conditions
- Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
- Interventions
- Microdevices, Standard of care therapy, Standard of care systemic therapy
- Device · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- No intervention
- Other
- Lead sponsor
- American Dental Association
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Stroke, Ischemic
- Interventions
- Penumbra System
- Device
- Lead sponsor
- Penumbra Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Englewood, Colorado • Tampa, Florida
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine and Zidovudine, Cyclosporine, Hepatitis A Vaccine (Inactivated), Efavirenz, Pneumococcal Conjugate Vaccine, Heptavalent, Rabies Vaccine
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 15
- States / cities
- Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 23
- States / cities
- Roseville, California • San Diego, California • Walnut Creek, California + 17 more